Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 Biomarker phenotype BEFREE Bcl-2 is a prime target for novel therapeutics because it is elevated in many forms of cancer and contributes to cancer progression and therapy resistance based on its ability to inhibit apoptosis. 19056433 2009
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 Biomarker phenotype BEFREE The mitochondrial apoptosis pathway is controlled by an interaction of multiple BCL-2 family proteins, and plays a key role in tumour progression and therapy responses. 27663504 2017
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 GeneticVariation phenotype BEFREE We conclude that, in contrast to its role in gastric neoplasia, bcl-2 alterations are not an important molecular marker in the neoplastic progression of Barrett's mucosa. 8552577 1996
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 AlteredExpression phenotype BEFREE Inhibition of apoptosis through bcl-2 protein expression appears to be specifically associated with promotion of intestinal-type gastric adenocarcinoma but does not appear to be active and/or correlated with tumor progression. 7712429 1995
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 Biomarker phenotype BEFREE Interaction between p53, Bcl-2, and other products of tumor suppressor genes or oncogenes are probably critical in tumor progression and response to treatment. 10494513 1999
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 AlteredExpression phenotype BEFREE Expression of the proto-oncogene Bcl-2 is associated with tumor progression. 17237270 2007
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 AlteredExpression phenotype BEFREE Furthermore, the expression of integrins and Bcl-2 in LCs had a tendency to correlate with the clinical stage of cancer progression, including lymph node metastasis. 23108890 2013
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 AlteredExpression phenotype BEFREE Loss of anti-mitotic effects of Bcl-2 with retention of anti-apoptotic activity during tumor progression in a mouse model. 10597263 2000
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 AlteredExpression phenotype BEFREE Toward this aim, we analyzed, using immunohistochemistry, the expression of the p53 gene and of its transcriptional target genes bax, bcl2, and waf1 in preinvasive bronchial lesions from 69 patients with lung cancer and in similar lesions from 20 patients with no cancer progression. p53 accumulation occurred with increasing frequency, from 19% in mild dysplasia to 36% in moderate dysplasia and 59% in carcinoma in situ, and was exclusively observed in patients with p53-positive carcinoma. 9676834 1998
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 AlteredExpression phenotype BEFREE Apoptosis inhibitor as a suppressor of tumor progression: expression of Bcl-2 eliminates selective advantages for p53-deficient cells in the tumor. 12170763 2002
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 AlteredExpression phenotype BEFREE With long-term I2, mammary tumor tissue became more sensitive to DOX, since a single injection of the lowest dose of DOX (4 mg/Kg) was enough to stop tumor progression and a second DOX4 injection on day 14 caused a significant and rapid decrease in tumor size, decreased the expression of chemoresistance markers (Bcl2 and survivin), and increased the expression of the apoptotic protein Bax and peroxisome proliferator-activated receptor type gamma. 23705792 2013
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 AlteredExpression phenotype BEFREE This suggests the possibility that alterations in p53 followed by over-expression of bcl-2 occur early in oral carcinogenesis resulting in defective apoptosis and subsequent tumor progression. 8697436 1996
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 Biomarker phenotype BEFREE Previous studies further suggest that such phospho-Bcl-2 regulation may influence tumor progression in colorectal and other cancers; however, phosphorylation status of the Ser70 of Bcl-2 (pSer70) in vivo in tumors remains obscure. 16243795 2006
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 AlteredExpression phenotype BEFREE In SCRT, long break in the treatment should be avoided because correlation between Ki-67, KU70, and BCL-2 expressions and pTNM after RT might indicate tumor progression. 24756926 2015
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 GeneticVariation phenotype BEFREE Typically, 1q21-23 rearrangements arise during tumor evolution and accompany disease-specific chromosomal rearrangements such as t(14;18) (BCL2) and t(8;14) (MYC), where they are thus thought to play an important role in tumor progression. 10618414 2000
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 GeneticVariation phenotype BEFREE Abnormal bcl-2 immunoreactivity in 1), the earliest precursor dysplastic lesions and its persistence throughout neoplastic progression and 2), contiguous morphologically unaltered nondysplastic epithelium suggests that bcl-2 alterations occur early during the morphological and molecular sequence of events leading to gastrointestinal epithelial neoplasia. 7856728 1995
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 Biomarker phenotype BEFREE Bcl-2 and Bcl-X(L) may play a critical role in cancer progression. 14613034 2003
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 AlteredExpression phenotype BEFREE We conclude from our results that bcl-2 protein is expressed by benign and malignant melanocytic tumors of the skin, but there is loss of bcl-2 protein expression with increasing tumor progression. 7777475 1995
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 AlteredExpression phenotype BEFREE Expression of bcl-2 is lost during tumor progression and is a strong prognostic parameter, suggesting that the regulation of apoptosis plays an important role in the behavior of cervical carcinomas. 9465813 1998
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 GeneticVariation phenotype BEFREE The frequency of apoptosis in colorectal neoplasia appears to increase in the course of tumor progression in association with a decline in bcl-2 expression, but is not influenced by p53 gene mutations. 9143411 1997
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 GeneticVariation phenotype BEFREE These data suggest that, in endometrial carcinomas, Bcl-2 and p53 alterations may play important roles in determining whether tumor progression from early to advanced stages will occur. 9292705 1997
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 Biomarker phenotype BEFREE These results indicate that Bcl-2 inhibits tumor progression in the liver, possibly by interfering with hepatocyte proliferation. 11212255 2001
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 AlteredExpression phenotype BEFREE Altered expression of Bcl-2 family proteins has been associated with tumorigenesis and tumor progression as well as resistance to radiotherapy and chemotherapy. 10547558 1999
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 AlteredExpression phenotype BEFREE BCL2 expression in CD105 positive neoangiogenic cells and tumor progression in angioimmunoblastic T-cell lymphoma. 22322190 2012
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 Biomarker phenotype BEFREE Moreover, the enhanced expression and/or activities of some drug resistance-associated molecules such as Bcl-2, Akt/molecular target of rapamycin (mTOR), nuclear factor-kappaB (NF-κB), hypoxia-inducible factors (HIFs), macrophage inhibitory cytokine-1 (MIC-1) and ATP-binding cassette (ABC) multidrug transporters frequently occur in cancer cells during cancer progression and metastases. 23994756 2015